Cell therapy for returning lymphoma study
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study collects data from adults with lymphoma that has come back or not improved after treatment, who have received or are receiving special cell therapies. The goal is to learn more about how these treatments work in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of B-cell lymphoma (like DLBCL, follicular, mantle cell, or others) or T-cell lymphoma that has come back or not responded to standard treatment
- You have had or are currently having a cell therapy, such as CAR-T cells, TIL therapy, or other immune cell treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of CAR-T cell therapy designed to treat certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard treatment. The cells are enhanced with IL-15 to help them work better.
This study tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that came back or did not improve after other treatments. The therapy uses your own immune cells to fight the cancer, and the study aims to see if it is safe and effective.
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
This trial tests a new type of cell therapy called CT1194D for people with certain B-cell blood cancers that have not responded to or have come back after standard treatment. The therapy is designed to find and destroy cancer cells that carry the CD19 or CD20 marker.
This trial tests a new treatment using your own immune cells, called CAR-T cells, that are modified to find and attack lymphoma cells with CD20 or CD30 markers. It is for people whose lymphoma has not responded to standard treatments or has returned after treatment.
This trial tests an experimental therapy called CT1195E, a type of 'living drug' made from your own immune cells to fight B-cell cancers that have returned or not responded to standard care. It's a phase 1 study, which means the main goal is to find a safe and effective dose, but you may benefit from the treatment.
Hear when a new Lymphoma, Non-Hodgkin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.